SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis()

INTRODUCTION: The effect of SARS-CoV-2 infection in patients with multiple sclerosis (MS) and the influence of disease-modifying therapies (DMT) for MS on COVID-19 are unknown. To date, patients with MS have not been shown to present greater risk of COVID-19 or more severe progression of the disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Piñar Morales, R., Ramírez Rivas, M.A., Barrero Hernández, F.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Neurología. Published by Elsevier España, S.L.U. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166535/
https://www.ncbi.nlm.nih.gov/pubmed/34103271
http://dx.doi.org/10.1016/j.nrleng.2021.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166535/
https://www.ncbi.nlm.nih.gov/pubmed/34103271
http://dx.doi.org/10.1016/j.nrleng.2021.03.002

Ejemplares similares